Laparoscopic Approach to Cancer of the Endometrium

NCT00096408 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 760

Last updated 2019-03-20

No results posted yet for this study

Summary

The primary objective of this study is to assess disease-free survival at 4.5 years postoperatively for women with apparent Stage 1 endometrial cancer, comparing patients who are randomised to receive Total Laparoscopic Hysterectomy (TLH) and patients who are randomised to receive Total Abdominal Hysterectomy (TAH).

Conditions

Interventions

PROCEDURE

Total Abdominal Hysterectomy

For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.

PROCEDURE

Total Laparoscopic Hysterectomy

The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    collaborator INDUSTRY
  • Tyco Healthcare Group

    collaborator INDUSTRY
  • Gynetech

    collaborator INDUSTRY
  • Queensland Government - Smart Health Research Grant

    collaborator UNKNOWN
  • National Health and Medical Research Council, Australia

    collaborator OTHER
  • Cancer Council Queensland

    collaborator OTHER
  • Cancer Council New South Wales

    collaborator OTHER
  • Cancer Council Victoria

    collaborator OTHER
  • Cancer Council Western Australia

    collaborator UNKNOWN
  • Cancer Australia

    collaborator OTHER
  • Queensland Centre for Gynaecological Cancer

    lead OTHER_GOV

Principal Investigators

  • Andreas Obermair · Queensland Centre for Gynaecological Cancer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2016-04-30
Completion
2018-12-31

Countries

  • Australia
  • Hong Kong
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00096408 on ClinicalTrials.gov